Figure 4.

Percentage of patients with a decrease from baseline of ≥1 point on the Glabellar Line Scale at maximum frown by treatment at select visits: response-evaluable population. Efficacy assessments were not performed at repeat treatments D2 or D14. On and after day 90, patients were eligible for a repeat treatment if their Glabellar Line Scale score was ≥2 at maximum frown as judged by the investigator. If a patient did not have a Glabellar Line Scale score ≥2, they were followed monthly until eligible for repeat treatment or until the study ended on day 365. D, day; IT, initial treatment; RT, repeat treatment.